Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs
Death, Sudden, Cardiac
|Official Title:||Genome-Wide Case-Only Study of Antihypertensive Drug-Gene Interactions|
- Genomic regions for each of the four major drug classes that influence drug and gene interaction [ Time Frame: Measured at completion of genetic analysis ] [ Designated as safety issue: No ]
- Ethnic-specific genetic variations for each of the four major drug classes that influence drug and gene interaction [ Time Frame: Measured at completion of genetic analysis ] [ Designated as safety issue: No ]
|Study Start Date:||September 2007|
|Study Completion Date:||November 2016|
|Primary Completion Date:||November 2016 (Final data collection date for primary outcome measure)|
Data and specimens from three large population-based studies of heart attack, sudden death, and stroke in people treated for high blood pressure with one of the four major classes of high blood pressure drugs
High blood pressure affects nearly one in three individuals in the United States. There are many factors that can cause high blood pressure, including family history and genetic traits, kidney disease, stress, diabetes, and diet. If left untreated, high blood pressure can increase one's risk for stroke, heart attack, and heart failure. There are four major classes of drugs used to treat high blood pressure, which include diuretics, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and calcium antagonists. Each class works differently in treating high blood pressure, and certain gene regions may affect the effectiveness of the various high blood pressure drugs. The purpose of this study is to identify new gene regions that may influence the effectiveness of the four major high blood pressure drug types in preventing a heart attack, sudden death, or stroke.
This study will draw upon specimens and data from three large population-based studies: the Group Health population, the Cardiovascular Heart Study, and the Jackson Heart Study. New samples of DNA and laboratory data will only be collected from participants in the Group Health population. The remaining samples will be pre-existing samples from the other two studies. Through a whole-genome study of the DNA samples, researchers will distinguish genomic regions of interest for the four major drug classes to identify associations between the drugs and genes in the population. Researchers will further genotype the "interesting" genomic regions discovered in the whole-genome study. Ethnic-specific genetic variations will also be identified to fully characterize the genetic variations. The study will be replicated to assess the validity of the findings.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00573092
|United States, Washington|
|Cardiovascular Health Research Unit|
|Seattle, Washington, United States, 98101|
|Principal Investigator:||Bruce M. Psaty, MD, PhD||University of Washington|